Scholtz & Company LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Scholtz & Company LLC bought a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 6,320 shares of the company’s stock, valued at approximately $3,684,000. Eli Lilly and Company accounts for approximately 1.8% of Scholtz & Company LLC’s investment portfolio, making the stock its 21st biggest holding.

Other large investors have also added to or reduced their stakes in the company. Simon Quick Advisors LLC boosted its stake in Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after purchasing an additional 278 shares during the period. Independent Advisor Alliance boosted its position in shares of Eli Lilly and Company by 1.7% during the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock valued at $18,810,000 after acquiring an additional 544 shares during the last quarter. Apexium Financial LP boosted its position in shares of Eli Lilly and Company by 1,819.1% during the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock valued at $6,667,000 after acquiring an additional 10,842 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $363,000. Finally, Terril Brothers Inc. boosted its position in shares of Eli Lilly and Company by 113.2% during the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after acquiring an additional 429 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.5 %

Shares of LLY traded up $12.70 during mid-day trading on Friday, hitting $849.99. 2,468,834 shares of the company’s stock traded hands, compared to its average volume of 2,293,791. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 1 year low of $432.34 and a 1 year high of $856.81. The firm has a market capitalization of $807.84 billion, a P/E ratio of 125.18, a PEG ratio of 1.85 and a beta of 0.36. The business’s 50-day moving average price is $775.80 and its 200-day moving average price is $708.73.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the previous year, the firm earned $1.62 earnings per share. The business’s revenue was up 26.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.61%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 20,383 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $836.32, for a total transaction of $17,046,710.56. Following the transaction, the insider now directly owns 98,188,427 shares of the company’s stock, valued at $82,116,945,268.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, major shareholder Lilly Endowment Inc sold 20,383 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $836.32, for a total transaction of $17,046,710.56. Following the sale, the insider now directly owns 98,188,427 shares in the company, valued at $82,116,945,268.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 337,804 shares of company stock valued at $278,236,284. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LLY. The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Finally, Argus boosted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $787.53.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.